Skip to main content
S&P 5007,636.31+1.12%DOW51,808.37+0.67%NASDAQ26,393.18+1.60%BTC$76,547.00+0.91%ETH$2,453.08+2.03%GOLD$4,390.70+0.07%OIL$101.91-0.51%
Smart Investors Daily
MB

NASDAQ · MBRX

Moleculin Biotech, Inc.

Healthcare · Biotechnology

$0.74

Up+$0.02 (+2.62%)

Updated Sep 17, 2026, 6:22 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.01M
P/E ratio
-0.18
Dividend yield
0.00%
52-week range
$0.16 – $15.75
Volume
273.85K
Avg. volume
194.99K

Price performance

MBRX price history

1M range · 20 trading sessions · Daily adjusted prices

MBRX closed at $0.74 after 20 trading sessions, up 29.37% for the selected period.

Last close
$0.74
Period change
+29.37%
Period low
$0.57
Period high
$0.83
Daily close
View OHLC price history
MBRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$0.76$0.7818$0.73$0.74273.85K
Sep 15, 2026$0.81$0.8175$0.7507$0.7516475.5K
Sep 14, 2026$0.75$0.82$0.75$0.7752719.2K
Sep 11, 2026$0.85$0.899$0.71$0.7151.93M
Sep 10, 2026$0.788$0.83$0.7735$0.8299533.63K
Sep 9, 2026$0.7711$0.8024$0.7506$0.765380.78K
Sep 8, 2026$0.735$0.80$0.724$0.7501736.84K
Sep 4, 2026$0.69$0.7375$0.68$0.7099775.6K
Sep 3, 2026$0.70$0.7299$0.6509$0.6755433.35K
Sep 2, 2026$0.655$0.70$0.6384$0.694350.02K
Sep 1, 2026$0.64$0.6548$0.62$0.65263.05K
Aug 31, 2026$0.64$0.672$0.62$0.6447301.03K
Aug 28, 2026$0.69$0.709$0.64$0.6499614.29K
Aug 27, 2026$0.62$0.7116$0.6093$0.68871.49M
Aug 26, 2026$0.6338$0.655$0.5901$0.60463.68K
Aug 25, 2026$0.60$0.669$0.598$0.611903.17K
Aug 24, 2026$0.61$0.62$0.5646$0.6093418.06K
Aug 21, 2026$0.5874$0.63$0.56$0.593294.18K
Aug 20, 2026$0.58$0.6361$0.55$0.59061.07M
Aug 19, 2026$0.6057$0.61$0.57$0.572663.13K

Latest MBRX news

The latest Smart Investors Daily articles mentioning MBRX.

Stock researchCompany · Overview

MBRX research

Overview

Company profile and research snapshot.

Company profile

Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$170.00
Implied upside
—
Analysts
9
MBRX recent ratings
DateFirmRatingTarget
Aug 28, 2026HC Wainwright & Co.Buy—
Mar 24, 2026HC Wainwright & Co.Buy—
Dec 11, 2025HC Wainwright & Co.Buy—
Sep 10, 2025HC Wainwright & Co.Buy—
Aug 27, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 11, 2026

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Access the video webcast here HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here. The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments. The on-d

Yahoo · Aug 27, 2026

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

- Video webcast now available here HOUSTON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it participated in the Virtual Investor “Why Now” on-demand conference. During the presentation, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, highlighted the Company's clinical progress and long-term opportunity, discussing encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annam

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By